Hyderabad-based biopharmaceutical company Suven Life Sciences has informed that it has been granted two product patents in South Africa and China for two of their new chemical entities. The South African patent is valid until 2024 and the other until 2025.

The granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts.

These patents are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like attention deficient hyperactivity, Alzheimer's, Parkinson, Schizophrenia and Huntington's.

Earlier this month, the company received European product patent from European Patent Office for its clinical candidate SUVN-502.

The company’s net profit declined 33.3% to Rs 1.94 crore on 24.4% growth in net sales to Rs 35 crore in Q4 March 2008 compared to Q4 March 2007.